Long-term survival of patients in the 123-patient Phase 1b CRC cohort was not limited to patients with favorable baseline characteristics, suggesting durable benefit may extend across a broader patient
ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engagement advances preparations across the Americas, Europe and Asia
Peer-reviewed NEST and UNICORN manuscripts report
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic complete response, within an overall 71% pathologic response rate
The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population
Side effects were mostly mild and
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday,
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor
Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combination
Armenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of
Survival estimate remained at 48% between years two and three, extending evidence of durable benefit
Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will
Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor
No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2
In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major
Previously announced oversubscribed $85 million private placement, with up to an additional $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution
ROBBIN addresses
